Evaxion A/S (EVAX) Stock Price, News & Analysis

Company Overview

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes. This approach aims to accelerate candidate discovery, refine antigen selection and enhance the precision of vaccine design. Evaxion’s pipeline encompasses a range of oncology programs targeting solid tumors as well as prophylactic vaccine programs focused on pathogens with high unmet medical need.

Evaxion traces its origins to academic collaborations at the University of Copenhagen and has evolved into a publicly traded company listed on the NASDAQ under the ticker EVAX. The company is led by CEO Thomas Krogh Nielsen, who brings extensive experience in biotech product development and corporate strategy. Under his leadership, Evaxion has entered into research partnerships with academic institutions and industry partners to advance its pipeline through preclinical and early clinical milestones.

Serving a global market, Evaxion collaborates with research centers and biopharma organizations across Europe and North America. Its AI-driven approach is positioned to address challenges in vaccine development by reducing time-to-candidate and improving the likelihood of clinical success. As Evaxion continues to expand its technology platform and advance its pipeline, the company aims to deliver novel immunotherapies and vaccines to patients worldwide.

Key Stats

• Today's Range: $3.03 to $3.07
• 50-Day Range: $2.79 to $3.86
• 52-Week Range: $2.52 to $12.15
• Volume: 4,182 shs
• Average Volume: 34,534 shs
• Market Capitalization: $25.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Moderate Buy

Evaxion A/S Stock Analysis - MarketRank™

Evaxion A/S scored higher than 54% of companies evaluated by MarketBeat, and ranked 447th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Evaxion A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Evaxion A/S has a consensus price target of $11.00, representing about 260.7% upside from its current price of $3.05.

Amount of Analyst Coverage

Evaxion A/S has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Evaxion A/S are expected to grow in the coming year, from ($0.50) to $5.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Evaxion A/S is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Evaxion A/S is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Evaxion A/S has a P/B Ratio of 1.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.43% of the float of Evaxion A/S has been sold short.

Short Interest Ratio / Days to Cover

Evaxion A/S has a short interest ratio ("days to cover") of 1.11, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Evaxion A/S has recently decreased by 28.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Evaxion A/S does not currently pay a dividend.

Dividend Growth

Evaxion A/S does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Evaxion A/S this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for EVAX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Evaxion A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

41.64% of the stock of Evaxion A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

11.04% of the stock of Evaxion A/S is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 8/11/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EVAX
• CIK: 1828253
• Web: www.evaxion-biotech.com
• Phone: 45-5353-1850
• Fax: N/A
• Employees: 60
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Evaxion A/S: $11.00
• High Price Target: $16.00
• Low Price Target: $9.00
• Potential Upside/Downside: +260.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.71 million
• Net Margins: N/A
• Pretax Margin: -141.96%
• Return on Equity: -73.56%
• Return on Assets: -37.45%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 5.85
• Quick Ratio: 5.85

Sales & Book Value

• Annual Sales: $7.53 million
• Price / Sales: 3.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.04 per share
• Price / Book: 1.50

Miscellaneous

• Outstanding Shares: 8,340,000
• Free Float: 4,867,000
• Market Cap: $25.47 million
• Optionable: No Data
• Beta: 0.29